PharmaDrug Inc. announced the appointment of Robert J. Steen as Chairman of the Board of Directors. Robert will replace Daniel Cohen, who will continue on in an advisory capacity to ensure a proper transition and steady state progress in the cepharanthine program. Robert has had a long career of successful entrepreneurship.

He has helped found and develop several businesses in several sectors including real estate acquisition and property management as well as financial tax products and consultancy. Most recently, Robert founded Trafalgar Addiction Treatment Centres in 2012 and helped develop the business until it was sold to a conglomerate in 2022. Robert has an M.B.A. from the Schulich School of Business.

The Company has also announced that Michael Forbes has left the board in order to pursue other opportunities. The Board would like to thank Mr. Forbes for his contributions to PharmaDrug.